<DOC>
	<DOCNO>NCT00735085</DOCNO>
	<brief_summary>A Randomized , Double Blind , Placebo Controlled , Phase 2 Dose Escalation Study Investigate Safety Pharmacokinetics Single Multiple I.V . Doses SLV334 Sequential Cohorts Patients Moderate Severe Traumatic Brain Injury .</brief_summary>
	<brief_title>A Phase 2a Dose Escalation Study With SLV334 Patients With Traumatic Brain Injury .</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient , age 16 70 year , inclusive . 2 . Sustained close [ nonpenetrating ] head trauma 8 hour initiation drug treatment study drug study hospital ; 3 . TBI diagnosed history , clinical examination GCS 12 less . 4 . Evidence TBI confirm abnormality CT scan 5 . Clinical indication monitor ICP 6 . Informed consent give . Exclusion Criteria 1 . Any spinal cord injury ; 2 . Pregnant lactating woman ; 3 . Patients penetrate head injury ; 4 . Bilaterally fix dilate pupil time randomization ; 5 . Coma suspect primarily due cause head injury drug alcohol overdose ; 6 . Severe multiple trauma major organ failure ( uncontrolled visceral bleeding , unstable cardiorespiratory renal function ) ; 7 . Known treatment another investigational drug therapy within 30 day injury . 8 . Life expectancy le 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Brain Injury</keyword>
</DOC>